title: Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?
abstract: Low molecular weight heparin is used in the treatment of patients with antiphospholipid syndrome, who develop thrombosis while being managed on oral anticoagulants. Although laboratory monitoring of this agent is not widely performed, it has been suggested to be useful in selected situations of high-risk thrombosis and bleeding. It is however not entirely clear, whether the dose should be altered on the basis of anti-Xa results in asymptomatic individuals.
authors.affiliation: Department of Haematology, Manchester Royal Infirmary, Oxford Road, Manchester, UK. jeckothachil@yahoo.co.uk
authors.forename: Jecko
authors.initials: J
authors.lastname: Thachil
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017153:Antibodies, Anticardiolipin / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000097:blood*; D058070:Asymptomatic Diseases; D017985:Dalteparin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D065427:Factor Xa Inhibitors; D006801:Humans; D019934:International Normalized Ratio; D007871:Leg Ulcer / Q000188:drug therapy / Q000209:etiology; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D012008:Recurrence; D019851:Thrombophilia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D013924:Thrombophlebitis / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control*; D014463:Ultrasonography; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D017153:Antibodies, Anticardiolipin; D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D016682:Lupus Coagulation Inhibitor; D014859:Warfarin; D017985:Dalteparin